Skip to main content

Table 2 Associations of QoL with clinical parameters at baseline and change in clinical parameters in follow-up

From: The clinical course of idiopathic pulmonary fibrosis and its association to quality of life over time: longitudinal data from the INSIGHTS-IPF registry

 

SGRQ total

EQ 5D VAS

UCSD-SOBQ

WHO-5

beta

95% CI

p-value

beta

95% CI

p-value

beta

95% CI

p-value

beta

95% CI

p-value

Female sex

5.42

1.13; 9.71

0.013

−3.36

−6.90; 0.18

0.063

13.56

6.41; 20.72

< 0.001

− 1.47

−2.60; − 0.33

0.011

Age

0.00

−0.19; 0.20

0.963

−0.18

− 0.34; − 0.02

0.029

0.35

0.04; 0.66

0.026

−0.05

− 0.10; 0.00

0.074

Age at first symptom onset in years

−0.10

− 0.28; 0.08

0.285

− 0.08

− 0.22; 0.07

0.323

0.17

− 0.11; 0.46

0.238

− 0.03

− 0.07; 0.02

0.299

Age at diagnosis in years

−0.09

− 0.28; 0.09

0.320

− 0.08

− 0.23; 0.07

0.290

0.18

− 0.11; 0.48

0.227

− 0.02

− 0.07; 0.03

0.400

Duration since first symptoms in years

0.73

0.28; 1.18

0.002

−0.51

−0.89; − 0.13

0.008

0.71

− 0.04; 1.46

0.062

− 0.09

− 0.21; 0.03

0.139

Disease duration in months

1.36

0.70; 2.02

< 0.001

−1.10

− 1.65; −0.55

< 0.001

1.70

0.64; 2.77

0.002

−0.25

−0.43; − 0.08

0.005

  < 3 months

1.00

  

1.00

  

1.00

  

1.00

  

 3 to < 6 months

−2.63

−9.30; 4.04

0.440

1.30

−4.28; 6.89

0.647

−4.48

−16.06; 7.11

0.449

0.54

−1.27; 2.34

0.560

 More than 6 months

6.54

2.53; 10.55

0.001

−5.10

−8.43; − 1.76

0.003

8.43

1.74; 15.12

0.014

−0.68

−1.76; 0.40

0.215

Number of comorbidities

 None

1.00

  

1.00

  

1.00

  

1.00

  

 1

3.55

−1.37; 8.47

0.157

−5.19

−9.23; − 1.16

0.012

9.93

2.05; 17.80

0.013

−0.86

−2.16; 0.44

0.195

 2

4.49

−0.63; 9.61

0.086

−6.46

−10.66; −2.26

0.003

10.11

1.88; 18.34

0.016

−1.02

−2.37; 0.33

0.140

 3

5.87

−0.04; 11.78

0.051

−7.75

− 12.62; −2.88

0.002

15.37

5.74; 24.99

0.002

−1.98

−3.55; −0.41

0.013

 4+

17.18

10.14; 24.23

< 0.001

−14.99

−20.88; −9.11

< 0.001

33.06

20.77; 45.35

< 0.001

−4.35

−6.24; −2.46

< 0.001

NHYA

 I

1.00

  

1.00

  

1.00

  

1.00

  

 II

16.07

9.16; 22.98

< 0.001

−12.61

−19.06; −6.15

< 0.001

22.28

10.78; 33.77

< 0.001

−1.86

−3.92; 0.21

0.078

 III

26.95

19.97; 33.93

< 0.001

−18.00

−24.49; − 11.50

< 0.001

38.29

26.65; 49.92

< 0.001

−3.82

−5.90; − 1.75

< 0.001

 IV

33.28

16.44; 50.13

< 0.001

−27.35

−41.90; − 12.81

< 0.001

51.63

24.63; 78.64

< 0.001

−8.69

−13.43; − 3.95

< 0.001

6MWD (m)

− 0.01

− 0.01; 0.00

0.217

0.00

0.00; 0.01

0.313

−0.01

− 0.03; 0.00

0.109

0.00

0.00; 0.00

0.423

FEV1% predicted

−0.55

−0.62; − 0.49

< 0.001

0.43

0.37; 0.49

< 0.001

− 0.80

− 0.91; − 0.70

< 0.001

0.09

0.07; 0.11

< 0.001

FVC % predicted

− 0.60

− 0.66; − 0.53

< 0.001

0.46

0.39; 0.53

< 0.001

−0.89

−1.00; − 0.78

< 0.001

0.11

0.09; 0.13

< 0.001

DLCO % predicted

−0.26

− 0.31; − 0.20

< 0.001

0.26

0.20; 0.33

< 0.001

− 0.35

− 0.44; − 0.25

< 0.001

0.04

0.02; 0.06

< 0.001

Change in FVC % predicted between baseline and 1-year follow-up

 Stable/increase

1.00

  

1.00

  

1.00

  

1.00

  

 Decrease by 0 to 10%

3.71

−0.55; 7.97

0.087

−2.90

−6.58; 0.77

0.122

4.08

−3.13; 11.29

0.267

−0.51

−1.67; 0.65

0.393

 Decrease by > 10%

9.08

2.48; 15.67

0.007

−8.07

−13.81; −2.33

0.006

11.24

0.32; 22.16

0.044

−1.30

−3.09; 0.50

0.156

Change in DLCO % predicted between baseline and 1-year follow-up

 Stable/increase

1.00

  

1.00

  

1.00

  

1.00

  

 Decrease by 0 to 10%

5.46

0.85; 10.08

0.020

−0.41

−4.43; 3.60

0.841

10.46

2.85; 18.07

0.007

−0.37

−1.62; 0.88

0.561

 Decrease by > 10%

7.79

0.85; 14.73

0.028

−3.93

−9.96; 2.10

0.201

10.74

−0.73; 22.21

0.067

−0.40

−2.28; 1.47

0.673

Change in FVC % predicted between baseline and last follow-up

 Stable/increase

1.00

  

1.00

  

1.00

  

1.00

  

 Decrease by 0 to 10%

3.44

−1.04; 7.92

0.133

−3.30

−7.08; 0.48

0.087

3.18

−4.45; 10.81

0.414

−0.22

−1.44; 0.99

0.719

 Decrease by > 10%

7.47

2.11; 12.83

0.006

−6.50

−11.02; − 1.99

0.005

8.80

−0.15; 17.75

0.054

−0.87

−2.32; 0.59

0.242

Change in DLCO % predicted between baseline and last follow-up

 Stable/increase

1.00

  

1.00

  

1.00

  

1.00

  

 Decrease by 0 to 10%

4.41

−0.52; 9.35

0.080

−1.42

−5.59; 2.75

0.505

11.09

2.94; 19.23

0.008

−0.44

−1.77; 0.89

0.518

 Decrease by > 10%

5.10

−0.51; 10.72

0.075

−2.47

−7.18; 2.25

0.305

8.24

−0.88; 17.36

0.077

−0.30

−1.80; 1.21

0.701

GAP index

3.29

1.95; 4.64

< 0.001

−3.41

−4.50; −2.33

< 0.001

6.47

4.36; 8.58

< 0.001

−0.50

− 0.86; − 0.14

0.007

 Stage I

1.00

  

1.00

  

1.00

  

1.00

  

 Stage II

5.69

0.74; 10.63

0.024

−7.04

−11.00; −3.08

< 0.001

16.51

8.69; 24.34

< 0.001

−0.92

−2.25; 0.41

0.177

 Stage III

12.93

7.42; 18.45

< 0.001

−13.51

− 17.96; −9.07

< 0.001

25.78

17.08; 34.47

< 0.001

− 1.79

−3.27; −0.30

0.019

Overall physician’s judgement of clinical course of IPF

 Stable disease

1.00

  

1.00

  

1.00

  

1.00

  

 Slow progression

7.79

3.51; 12.06

< 0.001

−3.52

−7.14; 0.10

0.056

11.13

4.04; 18.21

0.002

−1.08

−2.23; 0.08

0.068

 Rapid progression

13.16

6.22; 20.11

< 0.001

−9.52

−15.39; −3.65

0.001

19.89

8.32; 31.47

0.001

−2.72

−4.61; −0.83

0.005

 No judgement possible

−0.39

−4.93; 4.15

0.865

1.33

−2.43; 5.09

0.487

1.72

−5.72; 9.15

0.651

−0.01

−1.23; 1.20

0.986

  1. 6MWD six-minute walk distance; beta, regression coefficient, CI confidence interval, DLCO diffusing capacity of the lung for carbon monoxide, EQ-5D VAS EuroQol five-dimensional questionnaire, recorded as a visual analog scale, FEV1 Forced expiratory volume in 1 s, FVC forced vital capacity, GAP index Gender, Age, Physiology index, IPF idiopathic pulmonary fibrosis, NYHA New York Heart Association functional class, QoL quality of life, SD standard deviation, SGRQ St. George’s Respiratory Questionnaire, USCD-SOBQ University of California San Diego Shortness of Breath Questionnaire, WHO-5 World Health Organization-5 Well-Being Index